SEC Tracker
Get the app
Person · CIK 1704336

Michael Cloonan

President & CEO at Sionna Therapeutics; director at bluebird bio

Earlier: Sage Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$10.7M
Noticed on Form 144$5.8M
Bought on Form 4$0
Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Sionna Therapeutics SIONCommon StockDirectly765,393Sep 17, 2026 · Filing · EDGAR
Sionna Therapeutics SIONNon-Qualified Stock Option (right to buy)
exercise $7.18, expires Jan 1, 2036, into Common Stock
Directly436,100Sep 17, 2026 · Filing · EDGAR
bluebird bio BLUEStock Option (right to buy)
exercise $0.85, expires Jun 20, 2034, into Common Stock
Directly74,775Jun 20, 2024 · Filing · EDGAR
Sage TherapeuticsCommon StockDirectly2,102Jul 25, 2019 · Filing · EDGAR
Sage TherapeuticsStock Option (Right to Buy)
exercise $82.27, expires Feb 10, 2031, into Common Stock
Directly19,000Feb 10, 2021 · Filing · EDGAR

Sold and noticed by quarter

Michael Cloonan: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$4.4M$0Q1 2021: $0 noticed on Form 144Q1 2021: $0 sold on Form 4Q2 2021: $0 noticed on Form 144Q2 2021: $0 sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $0 sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $1.8M noticed on Form 144Q3 2025: $1.9M sold on Form 4Q4 2025: $4M noticed on Form 144Q4 2025: $4.4M sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2025$4.4M$4M
Q3 2025$1.9M$1.8M
Q2 2019$4.4MNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Sionna Therapeutics SION · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 21, 2025 · 6 notices
Oct 21, 202599,800 · ~$3.2MOct 21, 2025Sold as noticed Sold 99,800 in 4 sales, Oct 21 to Oct 21 · $3.6M Form 4Filing · EDGAR
Oct 16, 2025200 · ~$6KOct 16, 2025Not sold within 90 daysFiling · EDGAR
Oct 15, 202525,000 · ~$749KOct 15, 2025Sold as noticed Sold 25,000 in 2 sales, Oct 15 to Oct 16 · $781K Form 4Filing · EDGAR
Sep 26, 202525,000 · ~$688KSep 26, 2025Sold as noticed Sold 25,000 in 2 sales, Sep 26 to Sep 29 · $728K Form 4Filing · EDGAR
Aug 26, 202525,000 · ~$602KAug 26, 2025Sold as noticed Sold 25,000 in 2 sales, Aug 26 to Aug 27 · $624K Form 4Filing · EDGAR
Aug 20, 202525,000 · ~$537KAug 20, 2025Sold as noticed Sold 25,200 in 2 sales, Aug 20 to Oct 16 · $576K Form 4 (1) · Form 4 (2)Filing · EDGAR
Sales without a matching Form 144 · 1 sale
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Notice not machine-readable Sage Therapeutics: Sold 25,000 at $175.00 on May 22, 2019 · $4.4M (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Sionna Therapeutics SION President & CEO · filings 2025 to 2026 · sold $6.3M · $5.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 17, 2026Grant or award from the company+109,025656,368 directFiling · EDGAR
Sep 17, 2026Grant or award from the company+109,025765,393 directFiling · EDGAR
Sep 17, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+436,100436,100 directFiling · EDGAR
Sep 17, 2026Returned to the company
Non-Qualified Stock Option (right to buy)
−436,1000 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+436,100436,100 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted+13,324$6.11$81K560,667 directFiling · EDGAR
Oct 21, 2025Sale under a 10b5-1 plan−13,324$34.44$459K547,343 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted+30,049$6.11$184K577,392 directFiling · EDGAR
Oct 21, 2025Sale under a 10b5-1 plan−30,049$35.63$1.1M547,343 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted+22,895$6.11$140K570,238 directFiling · EDGAR
Oct 21, 2025Sale under a 10b5-1 plan−22,895$36.60$838K547,343 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted+33,532$6.11$205K580,875 directFiling · EDGAR
Oct 21, 2025Sale under a 10b5-1 plan−33,532$37.31$1.3M547,343 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−13,324139,618 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−30,049109,569 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−22,89586,674 directFiling · EDGAR
Oct 21, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−33,53253,142 directFiling · EDGAR
Oct 16, 2025Option or RSU exercised or converted+10,225$6.11$62K557,568 directFiling · EDGAR
Oct 16, 2025Sale under a 10b5-1 plan−10,225$31.46$322K547,343 directFiling · EDGAR
Oct 16, 2025Option or RSU exercised or converted+200$6.11$1K547,543 directFiling · EDGAR
Oct 16, 2025Sale under a 10b5-1 plan−200$34.00$7K547,343 directFiling · EDGAR
Oct 16, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−10,225153,142 directFiling · EDGAR
Oct 16, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−200152,942 directFiling · EDGAR
Oct 15, 2025Option or RSU exercised or converted+14,775$6.11$90K562,118 directFiling · EDGAR
Oct 15, 2025Sale under a 10b5-1 plan−14,775$31.11$460K547,343 directFiling · EDGAR
Oct 15, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−14,775163,367 directFiling · EDGAR
Sep 29, 2025Option or RSU exercised or converted+7,793$6.11$48K555,136 directFiling · EDGAR
Sep 29, 2025Sale under a 10b5-1 plan−7,793$29.70$231K547,343 directFiling · EDGAR
Sep 29, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−7,793178,142 directFiling · EDGAR
Sep 26, 2025Option or RSU exercised or converted+17,207$6.11$105K564,550 directFiling · EDGAR
Sep 26, 2025Sale under a 10b5-1 plan−17,207$28.85$496K547,343 directFiling · EDGAR
Sep 26, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−17,207185,935 directFiling · EDGAR
Aug 27, 2025Option or RSU exercised or converted+7,426$6.11$45K554,769 directFiling · EDGAR
Aug 27, 2025Sale under a 10b5-1 plan−7,426$25.01$186K547,343 directFiling · EDGAR
Aug 27, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−7,426203,142 directFiling · EDGAR
Aug 26, 2025Option or RSU exercised or converted+17,574$6.11$107K564,917 directFiling · EDGAR
Aug 26, 2025Sale under a 10b5-1 plan−17,574$24.96$439K547,343 directFiling · EDGAR
Aug 26, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−17,574210,568 directFiling · EDGAR
Aug 20, 2025Option or RSU exercised or converted+25,000$6.11$153K572,343 directFiling · EDGAR
Aug 20, 2025Sale under a 10b5-1 plan−25,000$22.75$569K547,343 directFiling · EDGAR
Aug 20, 2025Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−25,000228,142 directFiling · EDGAR
Feb 6, 2025Grant or award from the company
Stock Option (Right to Buy)
+450,252450,252 directFiling · EDGAR

bluebird bio BLUE Director · filings 2024 to 2025

DateTransactionSharesPriceValueHeld afterSource
Jun 2, 2025Returned to the company−1,8670 directFiling · EDGAR
Sep 30, 2024Grant or award from the company+37,35037,350 directFiling · EDGAR
Jun 20, 2024Grant or award from the company
Stock Option (right to buy)
+74,77574,775 directFiling · EDGAR

Sage Therapeutics Chief Business Officer · filings 2017 to 2021 · sold $4.4M

DateTransactionSharesPriceValueHeld afterSource
Feb 10, 2021Grant or award from the company
Stock Option (Right to Buy)
+19,00019,000 directFiling · EDGAR
May 1, 2020Grant or award from the company
Stock Option (Right to Buy)
+50,00050,000 directFiling · EDGAR
Apr 28, 2020Grant or award from the company
Stock Option (Right to Buy)
+9,4509,450 directFiling · EDGAR
Feb 12, 2020Grant or award from the company
Stock Option (Right to Buy)
+22,50022,500 directFiling · EDGAR
Jul 25, 2019Grant or award from the company+2,4503,190 directFiling · EDGAR
Jul 25, 2019Shares withheld for tax or exercise price−1,088$161.38$176K2,102 directFiling · EDGAR
May 22, 2019Option or RSU exercised or converted+25,000$73.43$1.8M25,461 directFiling · EDGAR
May 22, 2019Sale under a 10b5-1 plan−25,000$175.00$4.4M461 directFiling · EDGAR
May 22, 2019Option or RSU exercised or converted
Stock Option (Right to Buy)
−25,000160,000 directFiling · EDGAR
Feb 13, 2019Grant or award from the company
Stock Option (Right to Buy)
+24,50024,500 directFiling · EDGAR
Apr 2, 2018Grant or award from the company
Stock Option (Right to Buy)
+36,00036,000 directFiling · EDGAR
May 1, 2017Grant or award from the company
Stock Option (Right to Buy)
+185,000185,000 directFiling · EDGAR
All 29 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 18, 2026Form 4Sionna Therapeutics SIONFiling · EDGAR
Jan 6, 2026Form 4Sionna Therapeutics SIONFiling · EDGAR
Oct 22, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Oct 21, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Oct 17, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Oct 16, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Oct 15, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Sep 30, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Sep 26, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Aug 28, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 26, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Aug 21, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 20, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Jun 3, 2025Form 4bluebird bio BLUEFiling · EDGAR
Feb 10, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Feb 6, 2025Form 3Sionna Therapeutics SIONFiling · EDGAR
Oct 2, 2024Form 4bluebird bio BLUEFiling · EDGAR
Jun 24, 2024Form 4bluebird bio BLUEFiling · EDGAR
Jun 24, 2024Form 3bluebird bio BLUEFiling · EDGAR
Feb 12, 2021Form 4Sage TherapeuticsFiling · EDGAR
May 5, 2020Form 4Sage TherapeuticsFiling · EDGAR
Apr 30, 2020Form 4Sage TherapeuticsFiling · EDGAR
Feb 14, 2020Form 4Sage TherapeuticsFiling · EDGAR
Jul 29, 2019Form 4Sage TherapeuticsFiling · EDGAR
May 24, 2019Form 4Sage TherapeuticsFiling · EDGAR
Feb 15, 2019Form 4Sage TherapeuticsFiling · EDGAR
Apr 4, 2018Form 4Sage TherapeuticsFiling · EDGAR
May 4, 2017Form 4Sage TherapeuticsFiling · EDGAR
Apr 25, 2017Form 3Sage TherapeuticsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.